|
US5208020A
(en)
*
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
EP2977063A1
(de)
|
1999-06-25 |
2016-01-27 |
Genentech, Inc. |
Methoden zur Behandlung unter Verwendung von Anti-ErbB Antibody-Maytansinoid Konjugaten
|
|
EP2266607A3
(de)
|
1999-10-01 |
2011-04-20 |
Immunogen, Inc. |
Immunokonjugate für Krebsbehandlung
|
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
|
US6333410B1
(en)
*
|
2000-08-18 |
2001-12-25 |
Immunogen, Inc. |
Process for the preparation and purification of thiol-containing maytansinoids
|
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
|
US20050107595A1
(en)
*
|
2001-06-20 |
2005-05-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
US7803915B2
(en)
*
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
|
EP1409549A4
(de)
|
2001-06-20 |
2007-10-24 |
Genentech Inc |
Zusammensetzungen und verfahren für die diagnose und behandlung von tumoren
|
|
US20040235068A1
(en)
*
|
2001-09-05 |
2004-11-25 |
Levinson Arthur D. |
Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
|
|
EP2143438B1
(de)
|
2001-09-18 |
2011-07-13 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
|
|
US20110045005A1
(en)
|
2001-10-19 |
2011-02-24 |
Craig Crowley |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
|
AU2002367318B2
(en)
|
2002-01-02 |
2007-07-12 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
KR20040101502A
(ko)
|
2002-04-16 |
2004-12-02 |
제넨테크, 인크. |
종양의 진단 및 치료 방법 및 이를 위한 조성물
|
|
US20090068178A1
(en)
*
|
2002-05-08 |
2009-03-12 |
Genentech, Inc. |
Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
|
|
WO2004015119A2
(en)
*
|
2002-08-08 |
2004-02-19 |
Smithkline Beecham Corporation |
Methods for the isolation and purification of ansamitocins
|
|
US7432088B2
(en)
*
|
2003-05-08 |
2008-10-07 |
Immunogen Inc. |
Methods for the production of ansamitocins
|
|
ATE516047T1
(de)
|
2003-05-09 |
2011-07-15 |
Diadexus Inc |
Ovr110-antikörperzusammensetzungen und anwendungsverfahren
|
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
|
ES2863498T3
(es)
|
2003-05-20 |
2021-10-11 |
Immunogen Inc |
Agentes citotóxicos mejorados que comprenden nuevos maitansinoides
|
|
ES2751414T5
(es)
|
2003-07-08 |
2024-04-23 |
Novartis Pharma Ag |
Anticuerpos antagonistas a polipéptidos heterólogos IL-17 A/F
|
|
KR20060069825A
(ko)
*
|
2003-08-01 |
2006-06-22 |
제넨테크, 인크. |
제한된 다양성을 갖는 항체 ｃｄｒ 폴리펩티드 서열
|
|
AU2004291141B2
(en)
|
2003-11-17 |
2009-06-11 |
Genentech, Inc. |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
|
BRPI0417107A
(pt)
|
2003-12-19 |
2007-02-06 |
Genentech Inc |
fragmento de anticorpo, métodos de preparação do fragmento de anticorpo, ácido nucléico isolado, composições, célula hospedeira e métodos de fabricação e de geração de fragmento de anticorpo
|
|
CN114053429A
(zh)
*
|
2004-06-01 |
2022-02-18 |
健泰科生物技术公司 |
抗体-药物偶联物和方法
|
|
CN102641503A
(zh)
|
2004-07-20 |
2012-08-22 |
健泰科生物技术公司 |
血管生成素样4蛋白抑制剂，组合，以及其用途
|
|
BRPI0512482A
(pt)
|
2004-07-26 |
2008-03-11 |
Genentech Inc |
método de identificação de uma substáncia inibidora candidata e molécula antagonista
|
|
CA2486285C
(en)
*
|
2004-08-30 |
2017-03-07 |
Viktor S. Goldmakher |
Immunoconjugates targeting syndecan-1 expressing cells and use thereof
|
|
CN104710532B
(zh)
|
2004-09-03 |
2019-01-18 |
健泰科生物技术公司 |
人源化的抗-β7拮抗剂及其应用
|
|
DK1791565T3
(en)
|
2004-09-23 |
2016-08-01 |
Genentech Inc |
Cysteingensplejsede antibodies and conjugates
|
|
EP1841793B1
(de)
|
2005-01-07 |
2010-03-31 |
Diadexus, Inc. |
Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
|
|
US20110166319A1
(en)
*
|
2005-02-11 |
2011-07-07 |
Immunogen, Inc. |
Process for preparing purified drug conjugates
|
|
AU2006213662B2
(en)
|
2005-02-11 |
2010-08-05 |
Immunogen, Inc. |
Process for preparing stable drug conjugates
|
|
AU2006255686A1
(en)
|
2005-06-06 |
2006-12-14 |
Genentech, Inc. |
Transgenic models for different genes and their use for gene characterization
|
|
JP2009504183A
(ja)
|
2005-08-15 |
2009-02-05 |
ジェネンテック・インコーポレーテッド |
遺伝子破壊、それに関連する組成物および方法
|
|
EP2399609B1
(de)
*
|
2005-08-24 |
2015-03-18 |
ImmunoGen, Inc. |
Verfahren zur Herstellung von Maytansinoid-Antikörper-Konjugaten
|
|
US8679490B2
(en)
|
2005-11-07 |
2014-03-25 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
|
|
JP2009516514A
(ja)
|
2005-11-21 |
2009-04-23 |
ジェネンテック・インコーポレーテッド |
新規遺伝子破壊、それらに関する組成物および方法
|
|
RU2470941C2
(ru)
*
|
2005-12-02 |
2012-12-27 |
Дженентек, Инк. |
Связывающие полипептиды и их применения
|
|
CN105859886A
(zh)
|
2005-12-02 |
2016-08-17 |
健泰科生物技术公司 |
牵涉与il-22和il-22r结合的抗体的组合物和方法
|
|
EP1973951A2
(de)
*
|
2005-12-02 |
2008-10-01 |
Genentech, Inc. |
Bindende polypeptide mit eingeschränkten diversitätssequenzen
|
|
JP5358187B2
(ja)
|
2005-12-15 |
2013-12-04 |
ジェネンテック， インコーポレイテッド |
ポリユビキチンを標的とする方法と組成物
|
|
EP2402373B1
(de)
|
2006-01-05 |
2016-10-19 |
Genentech, Inc. |
ANTI-EPHB4-Antikörper sowie Verfahren zu deren Verwendung
|
|
CA2638133A1
(en)
|
2006-01-20 |
2007-11-08 |
Genentech, Inc. |
Anti-ephrinb2 antibodies and methods using same
|
|
AU2007233263A1
(en)
|
2006-02-17 |
2007-10-11 |
Genentech, Inc. |
Gene disruptons, compositions and methods relating thereto
|
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
|
WO2007126455A2
(en)
|
2006-04-05 |
2007-11-08 |
Genentech, Inc. |
Method for using boc/cdo to modulate hedgehog signaling
|
|
US20090288176A1
(en)
|
2006-04-19 |
2009-11-19 |
Genentech, Inc. |
Novel Gene Disruptions, Compositions and Methods Relating Thereto
|
|
PL2446904T3
(pl)
|
2006-05-30 |
2015-10-30 |
Genentech Inc |
Przeciwciała anty-CD22, ich immunokoniugaty oraz ich zastosowania
|
|
CA2658276A1
(en)
|
2006-07-18 |
2008-01-24 |
Sanofi-Aventis |
Antagonist antibody for the treatment of cancer
|
|
CA2662236A1
(en)
|
2006-09-12 |
2008-03-20 |
Genentech, Inc. |
Methods and compositions for the diagnosis and treatment of cancer
|
|
EP1914242A1
(de)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Neue Antikörper gegen CD38 zur Behandlung von Krebs
|
|
AU2007308792B2
(en)
|
2006-10-27 |
2013-01-24 |
Genentech, Inc. |
Antibodies and immunoconjugates and uses therefor
|
|
MX2009005466A
(es)
|
2006-11-22 |
2009-08-17 |
Adnexus A Bristol Myers Sqibb |
Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas, incluyendo receptor de factor de crecimiento tipo insulina-i.
|
|
EP2104513B1
(de)
|
2006-11-27 |
2015-05-20 |
diaDexus, Inc. |
Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
|
|
WO2008097497A2
(en)
|
2007-02-02 |
2008-08-14 |
Adnexus, A Bristol-Myers Squibb R & D Company |
Vegf pathway blockade
|
|
KR20090114443A
(ko)
|
2007-02-09 |
2009-11-03 |
제넨테크, 인크. |
항-Ｒｏｂｏ４ 항체 및 그의 용도
|
|
US8173813B2
(en)
|
2007-03-23 |
2012-05-08 |
Neuraxon, Inc. |
Quinolone and tetrahydroquinolone and related compounds having NOS inhibitory activity
|
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
|
US8114967B2
(en)
|
2007-03-27 |
2012-02-14 |
Sea Lane Biotechnologies Llc |
Constructs and libraries comprising antibody surrogate light chain sequences
|
|
PE20090321A1
(es)
|
2007-06-04 |
2009-04-20 |
Genentech Inc |
Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
|
|
WO2009012268A1
(en)
|
2007-07-16 |
2009-01-22 |
Genentech, Inc. |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
|
TW200918089A
(en)
|
2007-07-16 |
2009-05-01 |
Genentech Inc |
Humanized anti-CD79b antibodies and immunoconjugates and methods of use
|
|
EP3354662B1
(de)
|
2007-08-29 |
2020-08-19 |
Sanofi |
Humanisierte anti-cxcr5-antikörper, derivate davon und deren verwendungen
|
|
EP2050764A1
(de)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Neues polyvalentes bispezifisches Antikörperformat und Verwendung
|
|
NZ585500A
(en)
*
|
2007-11-12 |
2012-06-29 |
Theraclone Sciences Inc |
Antibodies which bind to an epitope in the extracellular domain of the matrix 2 ectodomain polypeptide of an influenza virus
|
|
US20110033476A1
(en)
*
|
2007-11-12 |
2011-02-10 |
Theraclone Sciences Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
|
TWI580694B
(zh)
|
2007-11-30 |
2017-05-01 |
建南德克公司 |
抗-ｖｅｇｆ抗體
|
|
PT2238168E
(pt)
*
|
2007-12-26 |
2014-07-18 |
Biotest Ag |
Agentes visando cd138 e suas utilizações
|
|
AR069979A1
(es)
*
|
2007-12-26 |
2010-03-03 |
Biotest Ag |
Metodo para disminuir los efectos secundarios citotoxicos y mejorar la eficacia de los inmunoconjugados
|
|
HUE024291T2
(en)
*
|
2007-12-26 |
2016-01-28 |
Biotest Ag |
Immunoconjugates and Applications for CD138
|
|
AR069978A1
(es)
*
|
2007-12-26 |
2010-03-03 |
Dana Farber Cancer Inst Inc |
Metodos y agentes para mejorar el reconocimiento de celulas de tumor que expresan cd 138
|
|
ES2414804T3
(es)
|
2008-01-18 |
2013-07-22 |
Genentech, Inc. |
Métodos y composiciones que se dirigen a la poliubiquitina
|
|
ES2587392T3
(es)
|
2008-01-31 |
2016-10-24 |
Genentech, Inc. |
Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
|
|
ES2542308T3
(es)
|
2008-03-10 |
2015-08-04 |
Theraclone Sciences, Inc. |
Composiciones y métodos para la terapia y diagnóstico de infecciones por citomegalovirus
|
|
US8663643B2
(en)
|
2008-03-18 |
2014-03-04 |
Genentech, Inc. |
Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
|
|
MX364200B
(es)
|
2008-04-09 |
2019-04-16 |
Genentech Inc |
Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
|
|
NO2281006T3
(de)
|
2008-04-30 |
2017-12-30 |
|
|
|
KR101361905B1
(ko)
*
|
2008-05-16 |
2014-02-21 |
제넨테크, 인크. |
베타7 인테그린 길항제를 이용한 위장관 염증 장애의 치료를 평가하기 위한 바이오마커의 용도
|
|
AR071874A1
(es)
|
2008-05-22 |
2010-07-21 |
Bristol Myers Squibb Co |
Proteinas de dominio de armazon basadas en fibronectina multivalentes
|
|
DK2318832T3
(da)
|
2008-07-15 |
2014-01-20 |
Academia Sinica |
Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder
|
|
MX2011002478A
(es)
|
2008-09-07 |
2011-04-05 |
Glyconex Inc |
Anticuerpo anti-glucoesfingolipido tipo i extendido, derivados del mismo y su uso.
|
|
AR073717A1
(es)
|
2008-10-01 |
2010-11-24 |
Genentech Inc |
Anticuerpos anti-notch2 de murino y humano, y metodos de uso
|
|
SG172219A1
(en)
|
2008-12-17 |
2011-07-28 |
Genentech Inc |
Hepatitis c virus combination therapy
|
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
|
AR075896A1
(es)
|
2009-03-20 |
2011-05-04 |
Genentech Inc |
Anticuerpos anti-her (factor de crecimiento epidermico)
|
|
MX345909B
(es)
|
2009-03-25 |
2017-02-22 |
Genentech Inc |
Anticuerpos anti-fgfr3 y métodos que los utilizan.
|
|
TW201038286A
(en)
|
2009-04-01 |
2010-11-01 |
Genentech Inc |
Anti-FcRH5 antibodies and immunoconjugates and methods of use
|
|
EP2414391B1
(de)
|
2009-04-02 |
2018-11-28 |
Roche Glycart AG |
Multispezifische antikörper, umfassend vollständige antikörper und einzelketten-fab-fragmente
|
|
CN102459340A
(zh)
*
|
2009-04-23 |
2012-05-16 |
特罗科隆科学有限公司 |
粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体
|
|
CA2759502C
(en)
|
2009-04-29 |
2021-02-09 |
Bio-Rad Laboratories, Inc. |
Purification of immunoconjugates
|
|
UY32560A
(es)
|
2009-04-29 |
2010-11-30 |
Bayer Schering Pharma Ag |
Inmunoconjugados de antimesotelina y usos de los mismos
|
|
CN102482345A
(zh)
|
2009-05-13 |
2012-05-30 |
航道生物技术有限责任公司 |
针对流感病毒的中和分子
|
|
EP2432803A2
(de)
|
2009-05-20 |
2012-03-28 |
Theraclone Sciences, Inc. |
Zusammensetzungen und verfahren zur therapie und diagnose von grippe
|
|
MX349210B
(es)
|
2009-06-03 |
2017-07-18 |
Immunogen Inc |
Métodos de conjugación.
|
|
JP5739880B2
(ja)
|
2009-06-04 |
2015-06-24 |
ノバルティス アーゲー |
ＩｇＧ結合のための部位を同定するための方法
|
|
BRPI1015234A2
(pt)
|
2009-06-22 |
2018-02-20 |
Medimmune Llc |
regiões fc projetadas para conjugação sítio específica.
|
|
RU2567803C2
(ru)
|
2009-07-31 |
2015-11-10 |
Дженентек, Инк. |
ИНГИБИРОВАНИЕ МЕТАСТАЗИРОВАНИЯ ОПУХОЛИ ПРИ ПОМОЩИ АНТАГОНИСТОВ Bv8 ИЛИ G-CSF
|
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
JP5887270B2
(ja)
|
2009-09-02 |
2016-03-16 |
ジェネンテック， インコーポレイテッド |
突然変異体ｓｍｏｏｔｈｅｎｅｄおよびその使用方法
|
|
US20120302737A1
(en)
|
2009-09-16 |
2012-11-29 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
|
US20110076232A1
(en)
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
|
AR078470A1
(es)
|
2009-10-02 |
2011-11-09 |
Sanofi Aventis |
Anticuerpos que se unen especificamente al receptor epha2
|
|
CN102791739B
(zh)
|
2009-10-19 |
2014-10-15 |
霍夫曼-拉罗奇有限公司 |
肝细胞生长因子激活剂的调控物
|
|
WO2011050188A1
(en)
|
2009-10-22 |
2011-04-28 |
Genentech, Inc. |
Anti-hepsin antibodies and methods using same
|
|
JP5819308B2
(ja)
|
2009-10-22 |
2015-11-24 |
ジェネンテック， インコーポレイテッド |
マクロファージ刺激タンパク質のヘプシン活性化を調節するための方法及び組成物
|
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
|
CA2780143A1
(en)
|
2009-11-05 |
2011-05-12 |
Genentech, Inc. |
Methods and composition for secretion of heterologous polypeptides
|
|
NZ599707A
(en)
|
2009-11-30 |
2014-07-25 |
Genentech Inc |
Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
|
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
CA2781682A1
(en)
|
2009-12-04 |
2011-06-09 |
Genentech, Inc. |
Multispecific antibodies, antibody analogs, compositions, and methods
|
|
ES2565208T3
(es)
|
2009-12-11 |
2016-04-01 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-VEGF-C y métodos de uso de los mismos
|
|
MY161868A
(en)
|
2009-12-23 |
2017-05-15 |
Genentech Inc |
Anti-bv8 antibodies and uses thereof
|
|
WO2011082187A1
(en)
|
2009-12-30 |
2011-07-07 |
Genentech, Inc. |
Methods for modulating a pdgf-aa mediated biological response
|
|
CN105001334A
(zh)
|
2010-02-10 |
2015-10-28 |
伊缪诺金公司 |
Cd20抗体及其用途
|
|
AU2011221226A1
(en)
|
2010-02-23 |
2012-08-16 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
AR080301A1
(es)
|
2010-02-24 |
2012-03-28 |
Immunogen Inc |
Anticuerpos e inmunoconjugados del receptor 1 de folato y sus usos
|
|
NZ602176A
(en)
|
2010-03-12 |
2015-01-30 |
Immunogen Inc |
Cd37-binding molecules and immunoconjugates thereof
|
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
|
US10338069B2
(en)
|
2010-04-12 |
2019-07-02 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
|
ES2617777T5
(es)
|
2010-04-23 |
2022-10-13 |
Hoffmann La Roche |
Producción de proteínas heteromultiméricas
|
|
CN102958941A
(zh)
|
2010-05-03 |
2013-03-06 |
霍夫曼-拉罗奇有限公司 |
用于肿瘤诊断和治疗的组合物和方法
|
|
AU2011261362B2
(en)
|
2010-06-03 |
2016-06-09 |
Genentech, Inc. |
Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
|
|
EP2579897A1
(de)
|
2010-06-08 |
2013-04-17 |
Genentech, Inc. |
Cystein-manipulierte antikörper und konjugate
|
|
JP5953303B2
(ja)
|
2010-07-29 |
2016-07-20 |
ゼンコア インコーポレイテッド |
改変された等電点を有する抗体
|
|
WO2012019024A2
(en)
|
2010-08-04 |
2012-02-09 |
Immunogen, Inc. |
Her3-binding molecules and immunoconjugates thereof
|
|
WO2012021786A2
(en)
|
2010-08-12 |
2012-02-16 |
Theraclone Sciences, Inc. |
Anti-hemagglutinin antibody compositions and methods of use thereof
|
|
EP2609111B1
(de)
|
2010-08-24 |
2017-11-01 |
F. Hoffmann-La Roche AG |
Bispezifische antikörper die ein disulfid-stabilisiertes fv enthalten
|
|
SI3556396T1
(sl)
|
2010-08-31 |
2022-09-30 |
Theraclone Sciences, Inc. |
Nevtralizacijska protitelesa proti virusu človeške imunske pomanjkljivosti (HIV)
|
|
WO2012034039A2
(en)
|
2010-09-10 |
2012-03-15 |
Apexigen, Inc. |
Anti-il-1 beta antibodies and methods of use
|
|
KR20130130709A
(ko)
|
2010-09-29 |
2013-12-02 |
어젠시스 인코포레이티드 |
191p4d12 단백질에 결합하는 항체 약물 컨쥬게이트(ａｄｃ)
|
|
EP3828205A1
(de)
|
2010-10-01 |
2021-06-02 |
Oxford BioTherapeutics Ltd |
Anti-ror1-antikörper
|
|
DK2625197T3
(en)
|
2010-10-05 |
2016-10-03 |
Genentech Inc |
Smoothened MUTANT AND METHODS OF USING THE SAME
|
|
WO2012058592A2
(en)
|
2010-10-29 |
2012-05-03 |
Immunogen, Inc. |
Non-antagonistic egfr-binding molecules and immunoconjugates thereof
|
|
NZ609619A
(en)
|
2010-10-29 |
2015-05-29 |
Immunogen Inc |
Novel egfr-binding molecules and immunoconjugates thereof
|
|
JP5766296B2
(ja)
|
2010-12-23 |
2015-08-19 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
|
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
|
WO2012106587A1
(en)
|
2011-02-04 |
2012-08-09 |
Genentech, Inc. |
Fc VARIANTS AND METHODS FOR THEIR PRODUCTION
|
|
US8916160B2
(en)
|
2011-02-14 |
2014-12-23 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
|
EP2681243B1
(de)
|
2011-03-03 |
2018-09-05 |
Apexigen, Inc. |
Anti-il-6-rezeptor-antikörper und verfahren zu ihrer verwendung
|
|
AU2012229188A1
(en)
|
2011-03-15 |
2013-09-26 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
|
TWI719112B
(zh)
|
2011-03-16 |
2021-02-21 |
賽諾菲公司 |
雙重ｖ區類抗體蛋白質之用途
|
|
MY171008A
(en)
|
2011-03-29 |
2019-09-23 |
Immunogen Inc |
Preparation of maytansinoid antibody conjugates by a one-step process
|
|
KR102272828B1
(ko)
|
2011-03-29 |
2021-07-05 |
이뮤노젠 아이엔씨 |
일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조
|
|
ES2709654T3
(es)
|
2011-04-29 |
2019-04-17 |
Apexigen Inc |
Anticuerpos anti-CD40 y métodos de uso
|
|
BR112013028890A2
(pt)
|
2011-05-09 |
2017-01-31 |
Univ Virginia Patent Foundation |
composições e métodos para o tratamento de câncer
|
|
PL3415531T3
(pl)
|
2011-05-27 |
2024-02-26 |
Glaxo Group Limited |
Białka wiążące antygen
|
|
TWI597065B
(zh)
|
2011-06-10 |
2017-09-01 |
梅爾莎納醫療公司 |
蛋白質－聚合物－藥物共軛體
|
|
SG195172A1
(en)
|
2011-06-21 |
2013-12-30 |
Immunogen Inc |
Novel maytansinoid derivatives with peptide linker and conjugates thereof
|
|
EP2736928B1
(de)
|
2011-07-28 |
2019-01-09 |
i2 Pharmaceuticals, Inc. |
Gegen erbb3-gerichtete sur-bindende proteine
|
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
|
KR20140068877A
(ko)
|
2011-08-17 |
2014-06-09 |
제넨테크, 인크. |
불응성 종양에서의 혈관신생의 억제
|
|
WO2013033069A1
(en)
|
2011-08-30 |
2013-03-07 |
Theraclone Sciences, Inc. |
Human rhinovirus (hrv) antibodies
|
|
UA118332C2
(uk)
|
2011-09-22 |
2019-01-10 |
Емджен Інк. |
Білок, що зв'язує антиген cd27l
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
EP2766392B1
(de)
|
2011-10-10 |
2019-07-17 |
Xencor, Inc. |
Verfahren zur reinigung von antikörpern
|
|
KR20140097205A
(ko)
|
2011-10-28 |
2014-08-06 |
제넨테크, 인크. |
흑색종을 치료하는 치료 조합물 및 방법
|
|
KR102027603B1
(ko)
|
2011-11-02 |
2019-10-01 |
아펙시젠, 인코포레이티드 |
항-kdr 항체 및 사용 방법
|
|
JP2014533954A
(ja)
|
2011-11-21 |
2014-12-18 |
イミュノジェン， インコーポレイテッド |
Ｅｇｆｒ抗体細胞傷害性薬物複合体による、ｅｇｆｒ療法に耐性である腫瘍の治療方法
|
|
US10117932B2
(en)
|
2011-12-08 |
2018-11-06 |
Biotest Ag |
Uses of immunoconjugates targeting CD138
|
|
EP3446707A1
(de)
|
2011-12-22 |
2019-02-27 |
i2 Pharmaceuticals, Inc. |
Surrogatbindungsproteine
|
|
US11147852B2
(en)
|
2011-12-23 |
2021-10-19 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
|
CN104520321A
(zh)
|
2012-01-09 |
2015-04-15 |
斯克利普斯研究所 |
超长互补决定区及其用途
|
|
EP3663314A1
(de)
|
2012-01-09 |
2020-06-10 |
The Scripps Research Institute |
Humanisierte antikörper mit ultralangem cdr3s
|
|
AU2013209512B2
(en)
|
2012-01-20 |
2017-08-03 |
I2 Pharmaceuticals, Inc. |
Surrobody cojugates
|
|
BR112014019579A2
(pt)
|
2012-02-10 |
2019-10-15 |
Genentech, Inc |
Anticorpo de cadeia única, polinucleotídeo, vetor, célula hospedeira, método de produção de um anticorpo de cadeia única, heteromultímero e método de produção do heteromultímero
|
|
WO2013130093A1
(en)
|
2012-03-02 |
2013-09-06 |
Genentech, Inc. |
Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
|
|
CN104379602B
(zh)
|
2012-03-08 |
2017-05-03 |
哈洛齐梅公司 |
具有条件活性的抗表皮生长因子受体抗体及其使用方法
|
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
|
AR090903A1
(es)
|
2012-05-01 |
2014-12-17 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-pmel17
|
|
JO3623B1
(ar)
|
2012-05-18 |
2020-08-27 |
Amgen Inc |
البروتينات المرتبطة بمولد المستضاد st2
|
|
EP2867253B1
(de)
|
2012-06-27 |
2016-09-14 |
F. Hoffmann-La Roche AG |
Verfahren zur auswahl und herstellung massgeschneiderter, hochselektiver und multispezifischer targeting-einheiten mit mindestens zwei verschiedenen bindungseinheiten sowie verwendungen davon
|
|
JP6309002B2
(ja)
|
2012-06-27 |
2018-04-11 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
標的に特異的に結合する少なくとも１つの結合実体を含む抗体Ｆｃ領域結合体を作製するための方法およびその使用
|
|
EP2885311B1
(de)
|
2012-08-18 |
2020-01-01 |
Academia Sinica |
Zelldurchlässige sonden zur identifikation und abbildung von sialidasen
|
|
SG10201701424QA
(en)
|
2012-08-23 |
2017-04-27 |
Agensys Inc |
Antibody drug conjugates (adc) that bind to 158p1d7 proteins
|
|
SG11201502429YA
(en)
|
2012-10-04 |
2015-04-29 |
Immunogen Inc |
Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
|
|
WO2014070934A1
(en)
|
2012-10-30 |
2014-05-08 |
Apexigen, Inc. |
Anti-cd40 antibodies and methods of use
|
|
LT3199552T
(lt)
|
2012-11-20 |
2020-04-10 |
Sanofi |
Anti-ceacam5 antikūnai ir jų panaudojimas
|
|
CN105849086B
(zh)
|
2012-11-24 |
2018-07-31 |
杭州多禧生物科技有限公司 |
亲水性链接体及其在药物分子和细胞结合分子共轭反应上的应用
|
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Ｂｃｍａ抗原結合蛋白質
|
|
CA2892863C
(en)
|
2012-12-10 |
2022-03-15 |
Mersana Therapeutics, Inc. |
Polymeric scaffold based on phf for targeted drug delivery
|
|
WO2014093640A1
(en)
|
2012-12-12 |
2014-06-19 |
Mersana Therapeutics,Inc. |
Hydroxy-polmer-drug-protein conjugates
|
|
EP3400961B1
(de)
|
2012-12-27 |
2021-02-24 |
Sanofi |
Anti-lamp1 antikörper und antikörper-konjugate und deren verwendung
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
JP6618362B2
(ja)
|
2013-01-14 |
2019-12-11 |
ゼンコア インコーポレイテッド |
新規異種二量体タンパク質
|
|
EP2945969A1
(de)
|
2013-01-15 |
2015-11-25 |
Xencor, Inc. |
Schnelle beseitigung von antigenkomplexen unter verwendung neuartiger antikörper
|
|
ES2728936T3
(es)
|
2013-01-25 |
2019-10-29 |
Amgen Inc |
Anticuerpos dirigidos contra CDH19 para melanoma
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
CA2902865A1
(en)
|
2013-03-14 |
2014-10-02 |
Genentech, Inc. |
Anti-b7-h4 antibodies and immunoconjugates
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
EP3514178A1
(de)
|
2013-03-15 |
2019-07-24 |
Novartis AG |
Antikörper-wirkstoff-konjugate
|
|
AU2014232416B2
(en)
|
2013-03-15 |
2017-09-28 |
Xencor, Inc. |
Modulation of T Cells with Bispecific Antibodies and FC Fusions
|
|
JP6594855B2
(ja)
|
2013-03-15 |
2019-10-23 |
ゼンコア インコーポレイテッド |
ヘテロ二量体タンパク質
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10239951B2
(en)
|
2013-05-08 |
2019-03-26 |
Zymeworks Inc. |
Bispecific HER2 and HER3 antigen binding constructs
|
|
HUE056580T2
(hu)
|
2013-05-30 |
2022-02-28 |
Kiniksa Pharmaceuticals Ltd |
Onkosztatin-M-receptor antigénjét kötõ fehérjék
|
|
US10086054B2
(en)
|
2013-06-26 |
2018-10-02 |
Academia Sinica |
RM2 antigens and use thereof
|
|
US9981030B2
(en)
|
2013-06-27 |
2018-05-29 |
Academia Sinica |
Glycan conjugates and use thereof
|
|
CN105814074B
(zh)
|
2013-07-18 |
2020-04-21 |
图鲁斯生物科学有限责任公司 |
具有超长互补决定区的人源化抗体
|
|
WO2015017146A2
(en)
|
2013-07-18 |
2015-02-05 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
|
EP3747465A1
(de)
|
2013-07-31 |
2020-12-09 |
BioNTech AG |
Diagnose und therapie von krebs mit krebsstammzellen
|
|
EP3027220A1
(de)
|
2013-08-01 |
2016-06-08 |
Agensys, Inc. |
An cd37-proteine bindende antikörper-wirkstoffkonjugate (adc)
|
|
CN104341504B
(zh)
|
2013-08-06 |
2017-10-24 |
百奥泰生物科技(广州)有限公司 |
双特异性抗体
|
|
AU2014317889B2
(en)
|
2013-09-06 |
2020-03-05 |
Academia Sinica |
Human iNKT cell activation using glycolipids with altered glycosyl groups
|
|
KR20160055253A
(ko)
|
2013-09-12 |
2016-05-17 |
할로자임, 아이엔씨 |
변형된 항-상피세포 성장인자 수용체 항체 및 이의 사용 방법
|
|
CA2922889A1
(en)
|
2013-09-17 |
2015-03-26 |
Genentech, Inc. |
Methods of using anti-lgr5 antibodies
|
|
DK3653228T3
(da)
|
2013-10-08 |
2024-07-15 |
Immunogen Inc |
Anti-folr1-immunkonjugatdoseringsregimer
|
|
EP3054992B1
(de)
|
2013-10-11 |
2019-08-14 |
Asana BioSciences, LLC |
Protein-polymer-wirkstoffkonjugate
|
|
JP6657075B2
(ja)
|
2013-10-11 |
2020-03-04 |
オックスフォード バイオセラピューティックス リミテッドＯｘｆｏｒｄ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ Ｌｔｄ |
がん治療のためのｌｙ７５に対する複合抗体
|
|
JP6420331B2
(ja)
|
2013-10-11 |
2018-11-07 |
メルサナ セラピューティクス，インコーポレイティド |
タンパク質−高分子−薬剤コンジュゲート
|
|
CA2925393C
(en)
|
2013-10-11 |
2023-03-07 |
Dimiter Dimitrov |
Tem8 antibodies and their use
|
|
EP3066118B1
(de)
|
2013-11-06 |
2020-01-08 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Alk-antikörper, konjugate und chimäre antigenrezeptoren und deren verwendung
|
|
MX2016006301A
(es)
|
2013-11-13 |
2016-12-16 |
Zymeworks Inc |
Construcciones de unión a antígeno monovalente que se dirigen a egfr y/o her2, y sus usos.
|
|
CN105814084B
(zh)
|
2013-12-13 |
2019-09-24 |
基因泰克公司 |
抗cd33抗体和免疫缀合物
|
|
CR20160271A
(es)
|
2013-12-16 |
2016-12-02 |
Genentech Inc |
Compuestos peptidométicos y sus conjugados de anticuerpo-fármaco
|
|
US9982041B2
(en)
|
2014-01-16 |
2018-05-29 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
KR20160111469A
(ko)
|
2014-01-24 |
2016-09-26 |
제넨테크, 인크. |
항-steap1 항체 및 면역접합체를 사용하는 방법
|
|
AU2015214264B2
(en)
|
2014-02-04 |
2018-12-20 |
Curis, Inc. |
Mutant Smoothened and methods of using the same
|
|
AU2014384434B2
(en)
|
2014-02-28 |
2016-11-03 |
Hangzhou Dac Biotech Co., Ltd |
Charged linkers and their uses for conjugation
|
|
JP6562942B2
(ja)
|
2014-03-27 |
2019-08-28 |
アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ |
反応性標識化合物およびその使用
|
|
PE20161431A1
(es)
|
2014-03-28 |
2017-01-22 |
Xencor Inc |
Anticuerpos biespecificos que se unen a cd38 y cd3
|
|
US10160812B2
(en)
|
2014-04-11 |
2018-12-25 |
Medimmune, Llc |
Bispecific HER2 antibodies
|
|
KR102603417B1
(ko)
|
2014-05-06 |
2023-11-20 |
제넨테크, 인크. |
포유동물 세포를 사용한 이종다량체 단백질의 생산
|
|
MX2016015162A
(es)
|
2014-05-22 |
2017-03-03 |
Genentech Inc |
Anticuerpos anti - gpc3 e inmunoconjugados.
|
|
JP2017518989A
(ja)
|
2014-05-27 |
2017-07-13 |
アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ |
抗ｃｄ２０糖操作抗体群およびその使用
|
|
CA2950423A1
(en)
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
|
US10005847B2
(en)
|
2014-05-27 |
2018-06-26 |
Academia Sinica |
Anti-HER2 glycoantibodies and uses thereof
|
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
|
US11332523B2
(en)
|
2014-05-28 |
2022-05-17 |
Academia Sinica |
Anti-TNF-alpha glycoantibodies and uses thereof
|
|
EP3194449A1
(de)
|
2014-07-24 |
2017-07-26 |
Xencor, Inc. |
Schnelle beseitigung von antigenkomplexen unter verwendung neuartiger antikörper
|
|
CA2954599A1
(en)
|
2014-08-12 |
2016-02-18 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates
|
|
KR102615681B1
(ko)
|
2014-08-28 |
2023-12-18 |
바이오아트라, 인코퍼레이티드 |
변형된 t 세포에 대한 조건부 활성 키메라 항원 수용체
|
|
JP2017526682A
(ja)
|
2014-09-02 |
2017-09-14 |
イミュノジェン， インコーポレイテッド |
抗体薬物複合体組成物の製剤化方法
|
|
JP6899321B2
(ja)
|
2014-09-08 |
2021-07-07 |
アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ |
糖脂質を使用するヒトｉＮＫＴ細胞活性化
|
|
RU2017107502A
(ru)
|
2014-09-12 |
2018-10-12 |
Дженентек, Инк. |
Антитела и конъюгаты, сконструированные введением цистеина
|
|
BR112017004802A2
(pt)
|
2014-09-12 |
2017-12-12 |
Genentech Inc |
anticorpos anti-cll-1 e imunoconjugados
|
|
CR20170131A
(es)
|
2014-09-12 |
2017-07-19 |
Genentech Inc |
Anticuerpos anti-her2 e inmunoconjugados
|
|
TW201625689A
(zh)
|
2014-09-12 |
2016-07-16 |
建南德克公司 |
抗－ｂ７－ｈ４抗體及免疫結合物
|
|
HUE049175T2
(hu)
|
2014-09-23 |
2020-09-28 |
Hoffmann La Roche |
Eljárás anti-CD79b immunkonjugátumok alkalmazására
|
|
AU2015324924B2
(en)
|
2014-10-01 |
2021-07-01 |
Medimmune, Llc |
Method of conjugating a polypeptide
|
|
CA2961439A1
(en)
|
2014-11-05 |
2016-05-12 |
Genentech, Inc. |
Anti-fgfr2/3 antibodies and methods using same
|
|
KR20170088905A
(ko)
|
2014-11-19 |
2017-08-02 |
이뮤노젠 아이엔씨 |
세포 결합 작용제-세포독성 작용제 접합체를 제조하기 위한 공정
|
|
JP2017536830A
(ja)
|
2014-11-26 |
2017-12-14 |
ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． |
Ｃｄ３及びｃｄ３８に結合するヘテロ二量体抗体
|
|
HUE055115T2
(hu)
|
2014-11-26 |
2021-10-28 |
Xencor Inc |
CD3-at és CD20-at kötõ heterodimer antitestek
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
CN107001482B
(zh)
|
2014-12-03 |
2021-06-15 |
豪夫迈·罗氏有限公司 |
多特异性抗体
|
|
AU2015358367B2
(en)
|
2014-12-04 |
2020-07-02 |
Celgene Corporation |
Biomolecule conjugates
|
|
US10428155B2
(en)
|
2014-12-22 |
2019-10-01 |
Xencor, Inc. |
Trispecific antibodies
|
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
CA2972072A1
(en)
|
2015-01-24 |
2016-07-28 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
|
JP2018510844A
(ja)
|
2015-01-24 |
2018-04-19 |
アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ |
がんマーカーおよびその使用方法
|
|
JP2018512597A
(ja)
|
2015-02-04 |
2018-05-17 |
ジェネンテック， インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
CN107614020A
(zh)
|
2015-03-18 |
2018-01-19 |
免疫生化公司 |
靶向细胞内肿瘤相关抗原的用于治疗癌症的缀合物
|
|
WO2016165762A1
(en)
|
2015-04-15 |
2016-10-20 |
Ganymed Pharmaceuticals Ag |
Drug conjugates comprising antibodies against claudin 18.2
|
|
CN116063543A
(zh)
|
2015-04-24 |
2023-05-05 |
豪夫迈·罗氏有限公司 |
多特异性抗原结合蛋白
|
|
ES2961346T3
(es)
|
2015-06-12 |
2024-03-11 |
Lentigen Tech Inc |
Procedimiento para tratar cáncer con células T modificadas genéticamente
|
|
EP3310813A1
(de)
|
2015-06-17 |
2018-04-25 |
Novartis AG |
Antikörper-wirkstoff-konjugate
|
|
CA2991973C
(en)
|
2015-07-12 |
2021-12-07 |
Suzhou M-Conj Biotech Co., Ltd. |
Bridge linkers for conjugation of a cell-binding molecule
|
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
|
MA42844A
(fr)
|
2015-09-17 |
2018-07-25 |
Immunogen Inc |
Combinaisons thérapeutiques comprenant des immunoconjugués anti-folr1
|
|
CN114181960B
(zh)
|
2015-10-09 |
2024-08-23 |
美天施生物科技有限公司 |
嵌合抗原受体和使用方法
|
|
WO2017066714A1
(en)
|
2015-10-16 |
2017-04-20 |
Compugen Ltd. |
Anti-vsig1 antibodies and drug conjugates
|
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
|
US11623957B2
(en)
|
2015-12-07 |
2023-04-11 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and PSMA
|
|
JP6991978B2
(ja)
|
2016-01-27 |
2022-02-03 |
メディミューン，エルエルシー |
定められるグリコシル化パターンを有する抗体を調製するための方法
|
|
EP3411396A1
(de)
|
2016-02-04 |
2018-12-12 |
Curis, Inc. |
Smoothened-mutant und verfahren zur verwendung davon
|
|
WO2017136623A1
(en)
|
2016-02-05 |
2017-08-10 |
Immunogen, Inc. |
Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
|
|
EP3426693A4
(de)
|
2016-03-08 |
2019-11-13 |
Academia Sinica |
Verfahren zur modularen synthese von n-glykanen und anordnungen davon
|
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
|
WO2017180842A1
(en)
|
2016-04-15 |
2017-10-19 |
Bioatla, Llc |
Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
|
|
WO2017196847A1
(en)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
|
|
WO2017194568A1
(en)
|
2016-05-11 |
2017-11-16 |
Sanofi |
Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
|
|
IL262404B2
(en)
|
2016-05-13 |
2024-04-01 |
Bioatla Llc |
Antibodies, Antibody Fragments and Their Immunomodules Against ROR2 and Their Uses
|
|
US20170370906A1
(en)
|
2016-05-27 |
2017-12-28 |
Genentech, Inc. |
Bioanalytical analysis of site-specific antibody drug conjugates
|
|
WO2017214182A1
(en)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
|
AU2017285218B2
(en)
|
2016-06-14 |
2024-08-22 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
|
EP3474901A1
(de)
|
2016-06-27 |
2019-05-01 |
Tagworks Pharmaceuticals B.V. |
Spaltbares, in der bioorthogonalen arzneimittelaktivierung verwendetes tetrazin
|
|
WO2018005706A1
(en)
|
2016-06-28 |
2018-01-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
|
CA3031559A1
(en)
|
2016-08-02 |
2018-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
|
|
WO2018027204A1
(en)
|
2016-08-05 |
2018-02-08 |
Genentech, Inc. |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
|
WO2018039274A1
(en)
|
2016-08-22 |
2018-03-01 |
CHO Pharma Inc. |
Antibodies, binding fragments, and methods of use
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
US11453712B2
(en)
|
2016-09-02 |
2022-09-27 |
Lentigen Technology Inc. |
Compositions and methods for treating cancer with DuoCARs
|
|
JP7142630B2
(ja)
|
2016-10-14 |
2022-09-27 |
ゼンコア インコーポレイテッド |
ＩＬ１５／ＩＬ１５Ｒαヘテロ二量体ＦＣ－融合タンパク質
|
|
US11278629B2
(en)
|
2016-11-02 |
2022-03-22 |
Debiopharm International, S.A. |
Methods for improving anti-CD37 immunoconjugate therapy
|
|
KR20220147721A
(ko)
|
2016-11-14 |
2022-11-03 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
|
EP3468991A1
(de)
|
2016-11-21 |
2019-04-17 |
cureab GmbH |
Anti-gp73-antikörper und immunkonjugate
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
US11236171B2
(en)
|
2016-12-21 |
2022-02-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies specific for FLT3 and uses thereof
|
|
CN117946283A
(zh)
|
2017-01-09 |
2024-04-30 |
莱蒂恩技术公司 |
用于用抗间皮素免疫治疗癌症的组合物和方法
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
GB201703876D0
(en)
|
2017-03-10 |
2017-04-26 |
Berlin-Chemie Ag |
Pharmaceutical combinations
|
|
EP3601356A1
(de)
|
2017-03-24 |
2020-02-05 |
Lentigen Technology, Inc. |
Zusammensetzungen und verfahren zur behandlung von krebs mit anti-cd33-immuntherapie
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
US11389480B2
(en)
|
2017-05-19 |
2022-07-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibody targeting TNFR2 for cancer immunotherapy
|
|
AR111963A1
(es)
|
2017-05-26 |
2019-09-04 |
Univ California |
Método y moléculas
|
|
WO2018237262A1
(en)
|
2017-06-22 |
2018-12-27 |
Mersana Therapeutics, Inc. |
METHODS FOR PRODUCING POLYMERIC MATRICES TRANSPORTING MEDICAMENTS, AND PROTEIN-POLYMER-MEDICINE CONJUGATES
|
|
WO2019005208A1
(en)
|
2017-06-30 |
2019-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
|
|
MA49517A
(fr)
|
2017-06-30 |
2020-05-06 |
Xencor Inc |
Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène
|
|
CA3066953A1
(en)
|
2017-06-30 |
2019-01-03 |
Lentigen Technology, Inc. |
Human monoclonal antibodies specific for cd33 and methods of their use
|
|
WO2019028051A1
(en)
|
2017-07-31 |
2019-02-07 |
Lentigen Technology, Inc. |
COMPOSITIONS AND METHODS FOR TREATING CANCER BY ANTI-CD19 / CD20 IMMUNOTHERAPY
|
|
CN107446050A
(zh)
|
2017-08-11 |
2017-12-08 |
百奥泰生物科技(广州)有限公司 |
Trop2阳性疾病治疗的化合物及方法
|
|
CN111225688A
(zh)
|
2017-08-22 |
2020-06-02 |
普渡研究基金会 |
靶向碳酸酐酶阳性癌症的基于fbsa的治疗和放射性成像缀合物
|
|
JP7035170B2
(ja)
|
2017-09-15 |
2022-03-14 |
レンティジェン・テクノロジー・インコーポレイテッド |
抗ｃｄ１９免疫療法によりがんを処置するための組成物および方法
|
|
JP7275118B2
(ja)
|
2017-10-16 |
2023-05-17 |
レンティジェン・テクノロジー・インコーポレイテッド |
抗ｃｄ２２免疫療法によってがんを処置するための組成物および方法
|
|
CN111601616A
(zh)
|
2017-10-24 |
2020-08-28 |
美真达治疗公司 |
用于耗尽cd117+细胞的组合物和方法
|
|
CA3082383A1
(en)
|
2017-11-08 |
2019-05-16 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-pd-1 sequences
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
JP2021506260A
(ja)
|
2017-12-15 |
2021-02-22 |
ジュノー セラピューティクス インコーポレイテッド |
抗ｃｃｔ５結合分子およびその使用方法
|
|
CA3086199A1
(en)
|
2017-12-19 |
2019-06-27 |
Xencor, Inc. |
Engineered il-2 fc fusion proteins
|
|
CA3086612A1
(en)
|
2017-12-20 |
2019-06-27 |
Lentigen Technology, Inc. |
Compositions and methods for treating hiv/aids with immunotherapy
|
|
BR112020018948A2
(pt)
|
2018-03-23 |
2021-01-05 |
Seattle Genetics, Inc. |
Uso de conjugados de fármaco e anticorpo que compreendem agentes de interrupção de tubulina para tratar tumor sólido
|
|
CA3096052A1
(en)
|
2018-04-04 |
2019-10-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
US11524991B2
(en)
|
2018-04-18 |
2022-12-13 |
Xencor, Inc. |
PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
|
|
CA3097741A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
|
WO2019212356A1
(en)
|
2018-05-04 |
2019-11-07 |
Tagworks Pharmaceuticals B .V. |
Tetrazines for high click conjugation yield in vivo and high click release yield
|
|
DK3788032T3
(da)
|
2018-05-04 |
2024-04-15 |
Tagworks Pharmaceuticals B V |
Forbindelser omfattende en linker til øgning af transcyklooctenstabilitet
|
|
EA202092967A1
(ru)
|
2018-05-30 |
2021-04-09 |
Дебиофарм Интернэшнл, С.А. |
Схемы приема иммуноконъюгата антитела против cd37
|
|
GB201809746D0
(en)
|
2018-06-14 |
2018-08-01 |
Berlin Chemie Ag |
Pharmaceutical combinations
|
|
JOP20200343A1
(ar)
|
2018-07-02 |
2020-12-31 |
Xencor Inc |
بروتين ربط مولد ضد مضاد لـ steap1
|
|
AU2019301675A1
(en)
|
2018-07-12 |
2021-01-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Affinity matured CD22-specific monoclonal antibody and uses thereof
|
|
CN112739340A
(zh)
|
2018-07-23 |
2021-04-30 |
美真达治疗公司 |
抗cd5抗体药物缀合物(adc)在同种异体细胞疗法中的用途
|
|
AU2019317565A1
(en)
|
2018-08-08 |
2021-02-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-2 and uses thereof
|
|
EP3853254A1
(de)
|
2018-09-20 |
2021-07-28 |
Lentigen Technology, Inc. |
Zusammensetzungen und verfahren zur behandlung von krebs mit anti-cd123-immuntherapie
|
|
JP7546554B2
(ja)
|
2018-09-26 |
2024-09-06 |
レンティジェン・テクノロジー・インコーポレイテッド |
抗ｃｄ１９／ｃｄ２２免疫療法によりがんを処置するための組成物および方法
|
|
SG11202103192RA
(en)
|
2018-10-03 |
2021-04-29 |
Xencor Inc |
Il-12 heterodimeric fc-fusion proteins
|
|
WO2020092385A1
(en)
|
2018-10-29 |
2020-05-07 |
Mersana Therapeutics, Inc. |
Cysteine engineered antibody-drug conjugates with peptide-containing linkers
|
|
CA3121244A1
(en)
|
2018-11-30 |
2020-06-04 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd38 immunotherapy
|
|
WO2020117257A1
(en)
|
2018-12-06 |
2020-06-11 |
Genentech, Inc. |
Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody
|
|
CA3125484A1
(en)
|
2019-01-08 |
2020-07-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross-species single domain antibodies targeting mesothelin for treating solid tumors
|
|
AU2020212534A1
(en)
|
2019-01-22 |
2021-07-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-1 and methods of use
|
|
EP3693023A1
(de)
|
2019-02-11 |
2020-08-12 |
Sanofi |
Verwendung von anti-ceacam5-immunkonjugaten zur behandlung von lungenkrebs
|
|
JP2022523155A
(ja)
|
2019-02-07 |
2022-04-21 |
サノフイ |
肺がんを処置するための抗ｃｅａｃａｍ５イムノコンジュゲートの使用
|
|
EP3930850A1
(de)
|
2019-03-01 |
2022-01-05 |
Xencor, Inc. |
Enpp3 und cd3 bindende heterodimere antikörper
|
|
WO2020181164A1
(en)
|
2019-03-06 |
2020-09-10 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with self-driving chimeric antigen receptors
|
|
TW202108178A
(zh)
|
2019-05-14 |
2021-03-01 |
美商建南德克公司 |
使用抗CD79b免疫結合物治療濾泡性淋巴瘤之方法
|
|
CN118345101A
(zh)
|
2019-05-30 |
2024-07-16 |
莱蒂恩技术公司 |
用于用抗bcma免疫治疗来治疗癌症的组合物和方法
|
|
JP2022537543A
(ja)
|
2019-06-17 |
2022-08-26 |
タグワークス ファーマシューティカルス ビー．ブイ． |
高速で且つ効率的なクリック放出の為の化合物
|
|
IL289094A
(en)
|
2019-06-17 |
2022-02-01 |
Tagworks Pharmaceuticals B V |
Tetrazines for increasing the speed and yield of the "click release" reaction
|
|
CA3142833A1
(en)
|
2019-07-02 |
2021-01-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind egfrviii and their use
|
|
JPWO2021010326A1
(de)
|
2019-07-12 |
2021-01-21 |
|
|
|
BR112022007216A2
(pt)
|
2019-10-18 |
2022-08-23 |
Genentech Inc |
Métodos para tratamento de linfoma difuso, kit e imunoconjugado
|
|
EP4031250A1
(de)
|
2019-10-22 |
2022-07-27 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Gegen b7h3 (cd276) gerichtete hochaffine nanokörper zur behandlung von multiplen soliden tumoren
|
|
WO2021118968A1
(en)
|
2019-12-12 |
2021-06-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-drug conjugates specific for cd276 and uses thereof
|
|
JP2023522393A
(ja)
|
2020-04-24 |
2023-05-30 |
サノフイ |
抗ｃｅａｃａｍ５抗体コンジュゲートおよびセツキシマブを含有する抗腫瘍組み合わせ
|
|
WO2021214222A1
(en)
|
2020-04-24 |
2021-10-28 |
Sanofi |
Antitumor combinations containing anti-ceacam5 antibody conjugates, trifluridine and tipiracil
|
|
IL297311A
(en)
|
2020-04-24 |
2022-12-01 |
Sanofi Sa |
Antitumor combinations containing conjugates of antibodies to ceacam5 and folfox
|
|
EP4139359A1
(de)
|
2020-04-24 |
2023-03-01 |
Genentech, Inc. |
Verfahren zur verwendung von anti-cd79b-immunkonjugaten
|
|
JP2023522392A
(ja)
|
2020-04-24 |
2023-05-30 |
サノフイ |
抗ｃｅａｃａｍ５抗体コンジュゲートおよびフォルフィリを含有する抗腫瘍組み合わせ
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
|
WO2021262723A1
(en)
|
2020-06-22 |
2021-12-30 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy
|
|
US20230391852A1
(en)
|
2020-10-26 |
2023-12-07 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting sars coronavirus spike protein and uses thereof
|
|
WO2022099026A1
(en)
|
2020-11-05 |
2022-05-12 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
|
|
JP2023548538A
(ja)
|
2020-11-08 |
2023-11-17 |
シージェン インコーポレイテッド |
併用療法
|
|
CA3212665A1
(en)
|
2021-03-09 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
US11859012B2
(en)
|
2021-03-10 |
2024-01-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and GPC3
|
|
CA3215049A1
(en)
|
2021-04-10 |
2022-10-13 |
Baiteng ZHAO |
Folr1 binding agents, conjugates thereof and methods of using the same
|
|
WO2022226317A1
(en)
|
2021-04-23 |
2022-10-27 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
|
WO2022232612A1
(en)
|
2021-04-29 |
2022-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Lassa virus-specific nanobodies and methods of their use
|
|
EP4337266A1
(de)
|
2021-05-12 |
2024-03-20 |
Genentech, Inc. |
Verfahren zur verwendung von anti-cd79b-immunkonjugaten zur behandlung von diffusem grossem b-zell-lymphom
|
|
CN117396513A
(zh)
|
2021-05-28 |
2024-01-12 |
葛兰素史密斯克莱知识产权发展有限公司 |
治疗癌症的联合疗法
|
|
CN117500831A
(zh)
|
2021-06-09 |
2024-02-02 |
美国政府(由卫生和人类服务部的部长所代表) |
用于治疗实体瘤的靶向pd-l1的跨物种单结构域抗体
|
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
|
US11807685B2
(en)
|
2021-08-05 |
2023-11-07 |
The Uab Research Foundation |
Anti-CD47 antibody and uses thereof
|
|
WO2023019092A1
(en)
|
2021-08-07 |
2023-02-16 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
|
JP2024532537A
(ja)
|
2021-09-06 |
2024-09-05 |
ヴェラクサ バイオテック ゲーエムベーハー |
真核生物における遺伝暗号の拡張のための新規アミノアシルｔＲＮＡ合成酵素変異体
|
|
WO2023057893A1
(en)
|
2021-10-05 |
2023-04-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapies for treating cancer
|
|
KR20240099412A
(ko)
|
2021-11-05 |
2024-06-28 |
사노피 |
항-ceacam5 항체-약물 접합체 및 항-vegfr-2 항체를 함유하는 항종양 조합
|
|
EP4433170A1
(de)
|
2021-11-18 |
2024-09-25 |
Oxford BioTherapeutics Ltd |
Pharmazeutische kombinationen
|
|
EP4433096A1
(de)
|
2021-11-19 |
2024-09-25 |
Ardeagen Corporation |
Gpc3-bindende mittel, konjugate davon und verfahren zur verwendung davon
|
|
WO2023094525A1
(en)
|
2021-11-25 |
2023-06-01 |
Veraxa Biotech Gmbh |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
|
EP4186529A1
(de)
|
2021-11-25 |
2023-05-31 |
Veraxa Biotech GmbH |
Verbesserte antikörper-nutzlast-konjugate (aps), hergestellt durch ortsspezifische konjugation mittels genetischer codeerweiterung
|
|
TW202339804A
(zh)
|
2021-12-02 |
2023-10-16 |
法商賽諾菲公司 |
在癌症療法中用於患者選擇的ｃｅａ測定
|
|
AU2022402334A1
(en)
|
2021-12-02 |
2024-07-18 |
Sanofi |
Ceacam5 adc–anti-pd1/pd-l1 combination therapy
|
|
CA3239713A1
(en)
|
2021-12-08 |
2023-06-15 |
Edward A. LEMKE |
Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
|
|
CN118541173A
(zh)
|
2021-12-15 |
2024-08-23 |
图兰恩教育基金管理人 |
缀合物、其组合物及其相关方法
|
|
EP4372000A3
(de)
|
2022-02-15 |
2024-07-17 |
Tagworks Pharmaceuticals B.V. |
Maskiertes il12-protein
|
|
US20230338424A1
(en)
|
2022-03-02 |
2023-10-26 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
|
|
US11590169B1
(en)
|
2022-03-02 |
2023-02-28 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD123 immunotherapy
|
|
WO2024013724A1
(en)
|
2022-07-15 |
2024-01-18 |
Pheon Therapeutics Ltd |
Antibody-drug conjugates
|
|
WO2024026107A2
(en)
|
2022-07-28 |
2024-02-01 |
Lentigen Technology, Inc. |
Chimeric antigen receptor therapies for treating solid tumors
|
|
WO2024044743A1
(en)
|
2022-08-26 |
2024-02-29 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with fully human anti-cd20/cd19 immunotherapy
|
|
WO2024080872A1
(en)
|
2022-10-12 |
2024-04-18 |
Tagworks Pharmaceuticals B.V. |
Strained bicyclononenes
|
|
WO2024153789A1
(en)
|
2023-01-20 |
2024-07-25 |
Basf Se |
Stabilized biopolymer composition, their manufacture and use
|
|
WO2024180192A1
(en)
|
2023-03-01 |
2024-09-06 |
Sanofi |
Use of anti-ceacam5 immunoconjugates for treating neuroendocrine cancers expressing ceacam5
|
|
EP4427763A1
(de)
|
2023-03-06 |
2024-09-11 |
Sanofi |
Antitumorkombinationen mit anti-ceacam5-antikörper-wirkstoff-konjugaten, anti-vegfr-2-antikörpern und anti-pd1/pd-l1-antikörpern
|